Pharmacokinetic of Thoracic Paravertebral Ropivacaine

• Status: Active, not recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to investigate the pharmacokinetic of ropivacaine in patients undergoing ultrasound guided thoracic paravertebral block (TPVB) both after a single-bolus injection via the thoracic paravertebral catheter given before the start of surgery and after continuous thoracic paravertebral infusion that will start after the end of the procedure in order to achieve postoperative analgesia after open thoracotomy during the first 3 postoperative days

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Attikon Hospital
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• Age >18 years

• ASA I-III

• Open thoracotomy

Exclusion Criteria:

• Patient refusal

• Age <18 years

• Morbid obesity

• Scoliosis

• Previous thoracotomy

• Empyema

• Drug allergy

• Severe systemic disease

• ASA > III

• Hypoalbuminemia

• Urgent surgery

• Reoperation during the study period